These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37414639)

  • 1. The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions.
    Martinón-Torres F; Navarro-Alonso JA; Garcés-Sánchez M; Soriano-Arandes A
    Arch Bronconeumol; 2023 Sep; 59(9):581-588. PubMed ID: 37414639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
    Lee Mortensen G; Harrod-Lui K
    Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus infection and the need for immunization in Korea.
    Kim HY; Yun KW; Cheong HJ; Choi EH; Lee HJ
    Expert Rev Vaccines; 2023; 22(1):327-340. PubMed ID: 36960592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal RSV vaccine development. Where to from here?
    Gunatilaka A; Giles ML
    Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Rainisch G; Adhikari B; Meltzer MI; Langley G
    Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.
    Srikantiah P; Vora P; Klugman KP
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
    Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015.
    Hardelid P; Verfuerden M; McMenamin J; Smyth RL; Gilbert R
    Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
    Srikantiah P; Klugman KP
    BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Welliver RC; Papin JF; Preno A; Ivanov V; Tian JH; Lu H; Guebre-Xabier M; Flyer D; Massare MJ; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2020 Jan; 38(5):1258-1270. PubMed ID: 31761502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
    Wildenbeest JG; Zuurbier RP; Korsten K; van Houten MA; Billard MN; Derksen-Lazet N; Snape MD; Drysdale SB; Robinson H; Pollard AJ; Heikkinen T; Cunningham S; Leach A; Martinón-Torres F; Rodríguez-Tenreiro Sánchez C; Gómez-Carballa A; Bont LJ;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S606-S612. PubMed ID: 32794574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.